Applications and challenges of multivalent recombinantvaccines

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 3, 2013, Pages 457-461

  Naim, Hussein Y ^a,b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b Life Sciences Andvaccines   (Switzerland)

Author keywords

DNA; HIV; Live attenuated viruses; Measles; Recombinant vectors; Reverse genetics; SIV; Vaccines

Indexed keywords

ADENOVIRUS VECTOR; BACTERIAL VECTOR; DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MEASLES VIRUS VECTOR; NEUTRALIZING ANTIBODY; PARVOVIRUS VECTOR; PEPTIDE VACCINE; POXVIRUS VECTOR; RABIES VIRUS VECTOR; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VESICULAR STOMATITIS VECTOR; VIRUS VECTOR; DRUG CARRIER; LIVE VACCINE; VIRUS LIKE PARTICLE VACCINE; VIRUS VACCINE;

CELL CULTURE; CONFERENCE PAPER; EXPRESSION VECTOR; GENETIC STABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; NONHUMAN; PROTEIN EXPRESSION; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VACCINE PRODUCTION; VIRUS GENE; VIRUS GENOME; VIRUS LIKE AGENT; VIRUS RECOMBINANT; VIRUS REPLICATION; DRUG DEVELOPMENT; GENE VECTOR; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MEASLES VIRUS; PROCEDURES; TRENDS;

DRUG CARRIERS; DRUG DISCOVERY; GENETIC VECTORS; HUMANS; MEASLES VIRUS; VACCINES, ATTENUATED; VACCINES, DNA; VACCINES, SYNTHETIC; VACCINES, VIRUS-LIKE PARTICLE; VIRAL VACCINES;

EID: 84874674664     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.23220     Document Type: Conference Paper

References (31)

1. Plotkin SA.vaccines: past, present and future. Nat Med 2005; 11(Suppl):S5-11; PMID:15812490; http://dx.doi.org/10.1038/nm1209.
2. Plotkin SA, Gilbert PB. Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis 2012; 54:1615-7; PMID:22437237; http://dx.doi.org/10.1093/cid/cis238.
3. Girard MP, Plotkin SA. HIVvaccine development at the turn of the 21st century. Curr Opin HIV AIDS 2012; 7:4-9; PMID:22156840; http://dx.doi.org/10. 1097/COH.0b013e32834ddc96.
4. Johnston MI, Fauci AS. An HIVvaccine -challenges and prospects. N Engl J Med 2008; 359:888-90; PMID:18753644; http://dx.doi.org/10.1056/NEJMp0806162.
5. Reyes-Sandoval A, Harty JT, Todryk SM. Viral vectorvaccines make memory T cells against malaria. Immunology 2007; 121:158-65; PMID:17462077; http://dx.doi.org/10.1111/j.1365-2567.2006.02552.x. (Pubitemid 46663084)
6. Havenga M, Vogels R, Zuijdgeest D, Radosevic K, Mueller S, Sieuwerts M, et al. Novel replicationincompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells. J Genvirol 2006; 87:2135-43; PMID:16847108; http://dx.doi.org/10.1099/vir.0.81956-0.
7. Glück R, Burri KG, Metcalfe I. Adjuvant and antigen delivery properties of virosomes. Curr Drug Deliv 2005; 2:395-400; PMID:16305442; http://dx.doi.org/10.2174/156720105774370302.
8. Tangy F, Naim HY. Live attenuated measlesvaccine as a potential multivalent pediatric vaccination vector. Viral Immunol 2005; 18:317-26; PMID:16035943; http://dx.doi.org/10.1089/vim.2005.18.317.
9. Li L, Saade F, Petrovsky N. The future of human DNAvaccines. J Biotechnol 2012; 162:171-82; PMID:22981627; http://dx.doi.org/10.1016/j.jbiotec. 2012.08.012.
10. Zeltins A. Construction and Characterization of Virus-Like Particles. Rev Mol Biotechnol 2012; In Press.
11. Girard MP, Osmanov SK, Kieny MP. A review ofvaccine research and development: the human immunodeficiency virus (HIV).vaccine 2006; 24:4062-81; PMID:16530298; http://dx.doi.org/10.1016/j.vaccine. 2006.02.031.
12. Kim YC, Quan FS, Compans RW, Kang SM, Prausnitz MR. Formulation of microneedles coated with influenza virus-like particlevaccine. AAPS PharmSciTech 2010; 11:1193-201; PMID:20676947; http://dx.doi.org/10.1208/s12249-010-9471-3.
13. Elena Gómez C, Perdiguero B, Garcia-Arriaza J, Esteban M. Poxvirus vectors as HIV/AIDSvaccines in humans. Hum Vaccin Immunother 2012; 8:1192-207; PMID:22906946; http://dx.doi.org/10.4161/hv.20778.
14. Lynch A, Meyers AE, Williamson AL, Rybicki EP. Stability studies of HIV-1 Pr55gag virus-like particles made in insect cells after storage in various formulation media.virol J 2012; 9:210; PMID:22988963; http://dx.doi.org/10.1186/ 1743-422X-9-210.
15. Sauter SL, Rahman A, Muralidhar G. Non-replicating viral vector-based AIDSvaccines: interplay between viral vectors and the immune system. Curr HIV Res 2005; 3:157-81; PMID:15853721; http://dx.doi.org/10.2174/1570162053506900.
16. Billeter MA, Naim HY, Udem SA. Reverse genetics of measles virus and resulting multivalent recombinantvaccines: applications of recombinant measles viruses. Curr Top Microbiol Immunol 2009; 329:129-62; PMID:19198565; http://dx.doi.org/10.1007/978-3-540-70523-9-7.
17. Liniger M, Zuniga A, Naim HY. Use of viral vectors for the development ofvaccines. Expert Revvaccines 2007; 6:255-66; PMID:17408374; http://dx.doi.org/10.1586/14760584.6.2.255.
18. Spielhofer P, Bächi T, Fehr T, Christiansen G, Cattaneo R, Kaelin K, et al. Chimeric measles viruses with a foreign envelope. Jvirol 1998; 72:2150-9; PMID:9499071.
19. Mebatsion T, Conzelmann KK. Specific infection of CD4+ target cells by recombinant rabies virus pseudotypes carrying the HIV-1 envelope spike protein. Proc Natl Acad Sci U S A 1996; 93:11366-70; PMID:8876141; http://dx.doi.org/10. 1073/pnas.93.21.11366.
20. Mebatsion T, Finke S, Weiland F, Conzelmann KKA. A CXCR4/CD4 pseudotype rhabdovirus that selectively infects HIV-1 envelope protein-expressing cells. Cell 1997; 90:841-7; PMID:9298896; http://dx.doi.org/10.1016/S0092-8674(00) 80349-9.
21. Schnell MJ. Viral vectors as potential HIV-1vaccines. FEMS Microbiol Lett 2001; 200:123-9; PMID:11425463; http://dx.doi.org/10.1111/j.1574-6968.2001. tb10703.x.
22. Zuniga A, Wang Z, Liniger M, Hangartner L, Caballero M, Pavlovic J, et al. Attenuated measles virus as avaccine vector.vaccine 2007; 25:2974-83; PMID:17303293; http://dx.doi.org/10.1016/j.vaccine. 2007.01.064.
23. Ye L, Wen Z, Dong K, Wang X, Bu Z, Zhang H, et al. Induction of HIV neutralizing antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric protein-based DNA and VLPvaccines. PLoS One 2011; 6:e14813; PMID:21625584; http://dx.doi.org/10.1371/journal.pone.0014813.
24. Knuchel MC, Marty RR, Azzouz Morin TN, Ilter O, Zuniga A, Naim HY. Relevance of a pre-existing measles immunity prior immunization with a recombinant measles vector. Hum Vaccin Immunother 2012; In Press.
25. Wang Z, Hangartner L, Cornu TI, Martin LR, Zuniga A, Billeter MA, et al. Recombinant measles viruses expressing heterologous antigens of mumps and simian immunodeficiency viruses.vaccine 2001; 19:2329-36; PMID:11257357; http://dx.doi.org/10.1016/S0264-410X(00)00523-5.
26. Zuniga A, Liniger M, Azzouz Morin TN, Marty RR, Wiegand M, Ilter O, et al. Sequence and immunogenicity of a clinically approved novel measles virusvaccine vector. Hum Vaccin Immunother 2012; In Press.
27. Liniger M, Zuniga A, Morin TN, Combardiere B, Marty R, Wiegand M, et al. Recombinant measles viruses expressing single or multiple antigens of human immunodeficiency virus (HIV-1) induce cellular and humoral immune responses.vaccine 2009; 27:3299-305; PMID:19200842; http://dx.doi.org/10.1016/j. vaccine.2009.01.057.
28. Lee EM, Chung HK, Livesay J, Suschak J, Finke L, Hudacik L, et al. Molecular methods for evaluation ofvirological status of nonhuman primates challenged with simian immunodeficiency or simianhuman immunodeficiency viruses. Jvirol Methods 2010; 163:287-94; PMID:19878696; http://dx.doi.org/10.1016/j. jviromet.2009.10.012.
29. Watkins DI. HIVvaccine development. Top HIV Med 2010; 18:35-6; PMID:20516522.
30. Bolton DL, Santra S, Swett-Tapia C, Custers J, Song K, Balachandran H, et al. Priming T-cell responses with recombinant measlesvaccine vector in a heterologous prime-boost setting in non-human primates.vaccine 2012; 30:5991-8; PMID:22732429; http://dx.doi.org/10.1016/j.vaccine.2012.06.029.
31. McEnery R, Kresge KJ. First Evidence of Efficacy from Large-Scale HIVvaccine Trial Results from a trial in Thailand show that the combination of twovaccine candidates provides some protection against HIV infection. VAX, 2009; Vol. 07, No. 09.